Home LiteratureArticle Details
PMID: 11170353 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

The development of L2X2Ru=CHR olefin metathesis catalysts: an organometallic success story.

Accounts of chemical research ·Vol. 34 ·No. 1 ·2001-01-00 ·Pages 18-29

Trnka TM, Grubbs RH

Abstract

In recent years, the olefin metathesis reaction has attracted widespread attention as a versatile carbon-carbon bond-forming method. Many new applications have become possible because of major advances in catalyst design. State-of-the-art ruthenium catalysts are not only highly active but also compatible with most functional groups and easy to use. This Account traces the ideas and discoveries that were instrumental in the development of these catalysts, with particular emphasis on (PCy3)2Cl2Ru=CHPh and its derivatives. The discussion includes an analysis of trends in catalyst activity, a description of catalysts coordinated with N-heterocyclic carbene ligands, and an overview of ongoing work to improve the activity, stability, and selectivity of this family of L2X2Ru=CHR complexes.

MeSH Terms
Catalysis Organometallic Compounds/chemistry Ruthenium Compounds/chemistry
Chemicals
Organometallic Compounds Ruthenium Compounds
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Trnka T M
Arnold and Mabel Beckman Laboratory of Chemical Synthesis, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA.
Grubbs R H
Article Info
Journal
Accounts of chemical research
Abbr.
Acc Chem Res
ISSN
0001-4842
Published
2001-01-00
Pages
18-29
Language
English
Region
United States
NLM ID
0157313
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]